TYRA
Tyra Biosciences, Inc.22.97
+0.85+3.84%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.23BP/E (TTM)
-Basic EPS (TTM)
-1.88Dividend Yield
0%Recent Filings
8-K
Sells 4M shares for $126M
8-K
Launches dabogratinib 3x3 strategy
Tyra Biosciences unveiled its 'dabogratinib 3x3' strategy on March 2, 2026, zeroing in on three Phase 2 trials for LG-UTUC, IR NMIBC, and ACH after dropping metastatic bladder cancer. Cash hit $256.0 million at year-end 2025, funding operations through at least 2027 despite a $119.9 million full-year net loss. Data readouts loom: SURF302 by mid-2026, BEACH301 later. Portfolio sharpened.
10-K
FY2025 results
Tyra Biosciences reported FY2025 ended December 31, 2025, as a clinical-stage biotech with no revenue disclosed in the 10-K, focused on advancing FGFR programs amid ongoing cash burn from R&D. Q4 saw key milestones including first patient dosing in SURF302 for IR NMIBC in August 2025 and FDA IND clearance for SURF303 in LG-UTUC in November 2025, building momentum toward Phase 2 readouts in 2026. Pipeline progress accelerated with BEACH301 safety data on track for H2 2026. Cash position stood at $297.3 million market value of non-affiliate shares as of June 30, 2025. No quarterly financials or capex detailed. Clinical trial delays threaten momentum.
8-K
Ashar named COO
Tyra Biosciences appointed Bhavesh Ashar as COO effective December 1, 2025, succeeding Daniel Bensen, who shifts to Chief Discovery Officer. Ashar, with deep oncology commercial experience at SpringWorks, Bayer, and Sanofi, gets $550,000 base, 40% target bonus, and options for 300,000 shares vesting over four years. Leadership realigns operations and discovery. Change-in-control protections boost retention.
8-K
Dosed patients, expanded trials
Tyra Biosciences dosed first patients in BEACH301 achondroplasia and SURF302 bladder cancer studies for dabogratinib, while securing FDA IND clearance to launch SURF303 in LG-UTUC next year. Cash hit $274.9 million, funding operations through 2027 despite Q3 net loss of $29.9 million, up from $24.0 million prior year. Interim data loom in 2026.
ATYR
aTyr Pharma, Inc.
0.73-0.00
AURA
Aura Biosciences, Inc.
6.18-0.15
ERAS
Erasca, Inc.
3.52+0.09
FBLG
FibroBiologics, Inc.
0.24-0.02
FBRX
Forte Biosciences, Inc.
23.27+1.31
KRRO
Korro Bio, Inc.
8.22+0.26
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
VTYX
Ventyx Biosciences, Inc.
8.21-0.13